Cathepsin S inhibition changes regulatory T‐cell activity in regulating bladder cancer and immune cell proliferation and apoptosis
暂无分享,去创建一个
Tao Chen | G. Sukhova | S. Liao | Cong-Lin Liu | G. Shi | Chun Wu | Chongzhe Yang | Hongqian Guo | Xiang Yan | Marcela M. Santos | Lijun Zhang | Jingyuan Ren
[1] P. Libby,et al. This information is current as Mice lprFas Lupus Erythematosus-like Manifestations in Cathepsin K Deficiency Ameliorates Systemic , 2017 .
[2] M. Abdelsalam,et al. Epstein–Barr virus and regulatory T cells in Egyptian paediatric patients with acute B lymphoblastic leukaemia , 2016, Journal of Clinical Pathology.
[3] B. Rocha,et al. Depletion of Regulatory T Cells Induces High Numbers of Dendritic Cells and Unmasks a Subset of Anti-Tumour CD8+CD11c+ PD-1lo Effector T Cells , 2016, PloS one.
[4] A. Tedgui,et al. Regulatory T-Cell Plasticity: Another Layer of Complexity in Atherosclerosis. , 2016, Circulation research.
[5] M. Hattori,et al. Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers , 2016, Nature Medicine.
[6] Shuai Li,et al. PD-L1 Expression Is Associated with Tumor FOXP3+ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient , 2016, Journal of Cancer.
[7] B. Undar,et al. Ex vivo evaluation of the effect of regulatory T cells on the anti-tumor activity of bortezomib in multiple myeloma. , 2016, Experimental hematology.
[8] C. Zhang,et al. Regulatory T cells in cardiovascular diseases , 2016, Nature Reviews Cardiology.
[9] F. Grillo,et al. Residual tumor micro-foci and overwhelming regulatory T lymphocyte infiltration are the causes of bladder cancer recurrence , 2016, Oncotarget.
[10] Yan Cai,et al. Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8+ T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression , 2016, Tumor Biology.
[11] J. M. Suh,et al. Depletion of Fat Tregs Prevents Age-Associated Insulin Resistance , 2015, Nature.
[12] Bin Shang,et al. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis , 2015, Scientific Reports.
[13] M. Farrar,et al. Adaptive Immunity to Leukemia Is Inhibited by Cross-Reactive Induced Regulatory T Cells , 2015, The Journal of Immunology.
[14] Nikhil S. Joshi,et al. Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. , 2015, Immunity.
[15] Claudia C. Preston,et al. Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer , 2015, Cancer Immunology, Immunotherapy.
[16] J. Wan,et al. Functional role of regulatory T cells in B cell lymphoma and related mechanisms. , 2015, International journal of clinical and experimental pathology.
[17] P. Libby,et al. Regulatory T cells in human and angiotensin II-induced mouse abdominal aortic aneurysms. , 2015, Cardiovascular research.
[18] L. Hansson,et al. CD4+ regulatory T cells in gastric cancer mucosa are proliferating and express high levels of IL-10 but little TGF-β , 2015, Gastric Cancer.
[19] D. DeBrota,et al. Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects. , 2014, British journal of clinical pharmacology.
[20] R. deLeeuw,et al. The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature , 2012, Clinical Cancer Research.
[21] K. Okumura,et al. Role for Cysteine Protease Cathepsins in Heart Disease: Focus on Biology and Mechanisms With Clinical Implication , 2012, Circulation.
[22] R. deLeeuw,et al. The Prognostic Value of FoxP 3 þ Tumor-In fi ltrating Lymphocytes in Cancer : A Critical Review of the Literature , 2012 .
[23] K. Okumura,et al. Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. , 2011, Hypertension.
[24] W. Patsch,et al. Potential Role of Regulatory T Cells in Reversing Obesity-Linked Insulin Resistance and Diabetic Nephropathy , 2011, Diabetes.
[25] B. Ristau,et al. Prognostic implications of lymph node involvement in bladder cancer: are we understaging using current methods? , 2011, BJU international.
[26] J. Wright,et al. Urinary bladder masses: techniques, imaging spectrum, and staging. , 2011, Journal of computer assisted tomography.
[27] D. Böckler,et al. Deficient CD4+CD25+ T Regulatory Cell Function in Patients With Abdominal Aortic Aneurysms , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[28] G. Li,et al. Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma , 2010, Clinical and experimental immunology.
[29] L. Terracciano,et al. High frequency of tumor‐infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair‐proficient colorectal cancer patients , 2010, International journal of cancer.
[30] D. Böckler,et al. Deficient CD 4 CD 25 T Regulatory Cell Function in Patients With Abdominal Aortic Aneurysms , 2010 .
[31] D. Sargent,et al. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. , 2009, Gastroenterology.
[32] Christophe Benoist,et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters , 2009, Nature Medicine.
[33] N. Zeps,et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M. Gur,et al. CD4+ CD25+ regulatory T-cells in acute coronary syndromes. , 2007, European heart journal.
[35] T. Tötterman,et al. Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. , 2007, The Journal of urology.
[36] G. Dranoff,et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. , 1999, Immunity.
[37] I. Summerhayes,et al. Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. , 1979, Journal of the National Cancer Institute.